Spots Global Cancer Trial Database for imab362
Every month we try and update this database with for imab362 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Early Access Program for Zolbetuximab | NCT06048081 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab | 18 Years - | Astellas Pharma Inc | |
| A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT03653507 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab oxaliplatin capecitabine placebo | 18 Years - | Astellas Pharma Inc | |
| A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | NCT03528629 | Gastric Cancer Gastro-esophage... | Zolbetuximab | 20 Years - | Astellas Pharma Inc | |
| Early Access Program for Zolbetuximab | NCT06048081 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab | 18 Years - | Astellas Pharma Inc | |
| Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer | NCT01197885 | Solid Tumors | IMAB362 | 18 Years - | Astellas Pharma Inc | |
| Early Access Program for Zolbetuximab | NCT06048081 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab | 18 Years - | Astellas Pharma Inc | |
| A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma | NCT03505320 | Pharmacokinetic... Gastric Cancer Gastro-esophage... Pharmacokinetic... Pharmacokinetic... | zolbetuximab oxaliplatin leucovorin fluorouracil Pembrolizumab folinic acid nivolumab Docetaxel | 18 Years - | Astellas Pharma Inc | |
| A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | NCT03816163 | Pancreatic Canc... Metastatic Panc... Metastatic Panc... | zolbetuximab nab-paclitaxel gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer | NCT01630083 | CLDN18.2-positi... CLDN18.2-positi... CLDN18.2-positi... | epirubicin oxaliplatin capecitabine zolbetuximab | 18 Years - | Astellas Pharma Inc | |
| A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer | NCT03504397 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab placebo oxaliplatin folinic acid fluorouracil | 18 Years - | Astellas Pharma Inc | |
| A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | NCT03816163 | Pancreatic Canc... Metastatic Panc... Metastatic Panc... | zolbetuximab nab-paclitaxel gemcitabine | 18 Years - | Astellas Pharma Inc | |
| A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | NCT03528629 | Gastric Cancer Gastro-esophage... | Zolbetuximab | 20 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
